212 related articles for article (PubMed ID: 36768931)
1. CD47-Dependent Regulation of Immune Checkpoint Gene Expression and MYCN mRNA Splicing in Murine CD8 and Jurkat T Cells.
Kaur S; Awad D; Finney RP; Meyer TJ; Singh SP; Cam MC; Karim BO; Warner AC; Roberts DD
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768931
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.
Nath PR; Pal-Nath D; Mandal A; Cam MC; Schwartz AL; Roberts DD
Cancer Immunol Res; 2019 Sep; 7(9):1547-1561. PubMed ID: 31362997
[TBL] [Abstract][Full Text] [Related]
3. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
Stirling ER; Terabe M; Wilson AS; Kooshki M; Yamaleyeva LM; Alexander-Miller MA; Zhang W; Miller LD; Triozzi PL; Soto-Pantoja DR
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36418073
[TBL] [Abstract][Full Text] [Related]
4. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.
Schwartz AL; Nath PR; Allgauer M; Lessey-Morillon EC; Sipes JM; Ridnour LA; Morillon Ii YM; Yu Z; Restifo NP; Roberts DD
Cancer Immunol Immunother; 2019 Nov; 68(11):1805-1817. PubMed ID: 31628526
[TBL] [Abstract][Full Text] [Related]
5. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.
Soto-Pantoja DR; Terabe M; Ghosh A; Ridnour LA; DeGraff WG; Wink DA; Berzofsky JA; Roberts DD
Cancer Res; 2014 Dec; 74(23):6771-83. PubMed ID: 25297630
[TBL] [Abstract][Full Text] [Related]
6. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Zain J; Smith DL; Akilov OE; Rosen ST; Feng M; Querfeld C
J Invest Dermatol; 2023 Aug; 143(8):1569-1578.e5. PubMed ID: 36863449
[TBL] [Abstract][Full Text] [Related]
8. Loss of CD47 alters CD8+ T cell activation
Nath PR; Pal-Nath D; Kaur S; Gangaplara A; Meyer TJ; Cam MC; Roberts DD
Oncoimmunology; 2022; 11(1):2111909. PubMed ID: 36105746
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
10. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.
Miller TW; Kaur S; Ivins-O'Keefe K; Roberts DD
Matrix Biol; 2013 Aug; 32(6):316-24. PubMed ID: 23499828
[TBL] [Abstract][Full Text] [Related]
11. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
12. Quercetin Limits Tumor Immune Escape through PDK1/CD47 Axis in Melanoma.
Li X; He X; Lin B; Li L; Deng Q; Wang C; Zhang J; Chen Y; Zhao J; Li X; Li Y; Xi Q; Zhang R
Am J Chin Med; 2024; 52(2):541-563. PubMed ID: 38490807
[TBL] [Abstract][Full Text] [Related]
13. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.
Kaur S; Chang T; Singh SP; Lim L; Mannan P; Garfield SH; Pendrak ML; Soto-Pantoja DR; Rosenberg AZ; Jin S; Roberts DD
J Immunol; 2014 Oct; 193(8):3914-24. PubMed ID: 25200950
[TBL] [Abstract][Full Text] [Related]
14. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
15. MYC regulates the antitumor immune response through CD47 and PD-L1.
Casey SC; Tong L; Li Y; Do R; Walz S; Fitzgerald KN; Gouw AM; Baylot V; Gütgemann I; Eilers M; Felsher DW
Science; 2016 Apr; 352(6282):227-31. PubMed ID: 26966191
[TBL] [Abstract][Full Text] [Related]
16. Interactions between CD47 and thrombospondin reduce inflammation.
Lamy L; Foussat A; Brown EJ; Bornstein P; Ticchioni M; Bernard A
J Immunol; 2007 May; 178(9):5930-9. PubMed ID: 17442977
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
[TBL] [Abstract][Full Text] [Related]
18. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
19. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors.
Kaur S; Soto-Pantoja DR; Stein EV; Liu C; Elkahloun AG; Pendrak ML; Nicolae A; Singh SP; Nie Z; Levens D; Isenberg JS; Roberts DD
Sci Rep; 2013; 3():1673. PubMed ID: 23591719
[TBL] [Abstract][Full Text] [Related]
20. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
